Rethinking child treatments

Evidence-based treatments - specifically for children

Releases

Releases

3. June, 2024

Cessatech announces superior simulated pain efficacy in children

Cessatech announces the final simulated efficacy data in children with CT001 from the abstract...

Read more

Releases

27. May, 2024

Cessatech reports first patient dosed in final Safety Study 0202 of lead product candidate CT001

Cessatech A/S announces that the Safety Study 0202 has now been initiated with dosing...

Read more

Releases

29. February, 2024

Annual Report 2023

Cessatech A/S publishes its annual report for the fiscal year 2023, which also includes...

Read more

Releases

9. January, 2024

Cessatech 2024 major milestones and focus

Now is the time – 2024 will be an extremely busy and hopefully exciting...

Read more

Releases

4. January, 2024

Q&A session – topline data from Study 0205

Link to release: (Link to Q&A session-image)

Read more

Facts about Children

Facts

18. March, 2024

Acute pain treatment – large unmet need, paediatrics receive least…mainly due to inadequate solutions

More than 20 million children annually, alone in Europe, are subject to acute pain...

Read more

Facts

12. February, 2024

Treating children is not just like treating small adults

  Giving medicine to children can’t be a one-size-fits-all approach. Their changing anatomy and...

Read more

Facts

25. August, 2023

New findings supporting CT001

Based on new findings in a 2023 meta-analysis by Fjendbo Galili et al., which...

Read more

Facts

15. March, 2022

Off-label use of medication in children continue to be the rule rather than the exception…

A systematic review of 31 studies with off-label prescription rates confirms the continued off-label...

Read more

Facts

3. March, 2022

Physical restraint of children in 79% of Scandinavian emergency departments

Physical restraint of children during painful procedures is used in 79% of Scandinavian emergency...

Read more

Experience

Proven track-record within drug development and product launches, in Europe, US and Asia.

The executive management team and the Board of Directors have a proven track-record within drug development, paediatric analgesic research, product launches and capital raising across all major markets.

Team
Lead Asset

CT001 – Nasal spray

Cessatech’s first product and lead asset, CT001, is an analgesic non-invasive nasal spray for children aged 1-17 years that experience acute pain or pain related to medical procedures. Today’s analgesic solutions often require an intravenous access which is not always feasible or easy and can be painful experience.

See details

Stay up to date!

Subscribe and get notified on Cessatech's latest news.
An acceptance email will be sent to you, please check your spam.